About 1 in 8 men in the United States will be diagnosed with prostate cancer during their lifetime, making it one of the most common cancers in men. But that risk is not evenly distributed. Age, race, family history, genetics, and certain environmental exposures all play a role in determining who is most likely to develop the disease.
Age Is the Strongest Risk Factor
Prostate cancer is overwhelmingly a disease of older men. The median age at diagnosis is 68, and the vast majority of cases occur after age 55. That said, about 10% of new diagnoses in the U.S. happen in men 55 or younger, so it’s not exclusively a disease of the elderly.
The cancer rarely appears before age 40. Risk begins climbing in a man’s late 40s and rises steeply through his 60s and 70s. This age pattern matters for screening decisions: most guidelines suggest discussing PSA testing with your doctor starting between ages 55 and 69, though men at higher risk may want to start that conversation at 40 or 45.
Black Men Face Significantly Higher Risk
Racial disparities in prostate cancer are among the starkest in all of oncology. Black men in the U.S. are diagnosed at a rate 60% higher than white men, and they tend to be diagnosed at a younger age. The gap in outcomes is even wider: prostate cancer mortality among Black men is roughly 2.3 times higher than among white men. Over a lifetime, about 18.2% of Black men will develop prostate cancer, compared to 13.3% of white men.
Asian American men sit at the opposite end of the spectrum, with some of the lowest incidence rates globally, ranging from 2 to 10 cases per 100,000 men in Asian countries. Hispanic men also have lower incidence and slightly better survival than white men after adjusting for age and diagnosis timing.
These disparities reflect a combination of genetic susceptibility, differences in access to care, and likely environmental and dietary factors. When researchers analyzed outcomes among more than 500,000 men who had surgery for prostate cancer and adjusted for clinical factors and access to care, a significant portion of the survival gap between racial groups narrowed, but it did not disappear entirely.
Family History Doubles or Triples Your Risk
Having a first-degree relative (father, brother, or son) diagnosed with prostate cancer roughly doubles or triples your risk. That risk climbs further with the number of affected relatives and drops with their age at diagnosis. In other words, if your brother was diagnosed at 52, that signals more risk than if your father was diagnosed at 75.
Doctors define “familial prostate cancer” as having either two first-degree relatives diagnosed at any age, or one first-degree relative plus two or more second-degree relatives (uncles, grandfathers) with the disease. If your family fits this pattern, earlier screening conversations are worth having.
Inherited Gene Mutations
Genetics account for a surprisingly large share of prostate cancer risk. Twin studies suggest that up to 42% of a man’s risk can be explained by inherited factors. Most of that comes from common genetic variations that each add a small amount of risk, but a few specific mutations carry dramatically higher odds.
The most significant is a mutation in the BRCA2 gene, the same gene linked to breast and ovarian cancer in women. Men who carry a BRCA2 mutation face an 8.6-fold increased risk of prostate cancer if they’re 65 or younger. These mutations appear in only 1% to 2% of all prostate cancer cases, but the cancers they produce tend to be more aggressive. BRCA1 mutations also raise risk, about 3.5-fold, though they’re found in less than half a percent of cases.
Certain populations carry these mutations at higher rates. Ashkenazi Jewish men have a relatively high prevalence of three specific founder mutations in BRCA1 and BRCA2. An Icelandic founder mutation in BRCA2 has also been well studied. If you have a known BRCA mutation in your family, screening guidelines generally recommend starting PSA testing at age 40.
Chemical and Occupational Exposures
Several workplace exposures have been linked to modestly elevated prostate cancer risk. A large meta-analysis found statistically significant increases for men exposed to pesticides (15% higher risk overall), chromium (19% higher), and those who work night shifts (25% higher). Airline pilots also showed a 41% increased risk, possibly related to cosmic radiation exposure at high altitudes.
Among pesticides, organochlorine compounds, a class that includes chlordane, heptachlor, and lindane, showed the clearest connection. One study of chlordecone exposure found a dose-response relationship, meaning risk rose in step with cumulative exposure, which strengthens the case for a real causal link. Organophosphate pesticides, by contrast, showed no increased risk.
Cadmium, often highlighted as a risk factor, showed a non-significant increase in risk in pooled analysis. The evidence is suggestive but not conclusive. Veterans exposed to Agent Orange are recognized by the VA as having increased prostate cancer risk, reflecting the herbicide’s organochlorine components. On the positive side, men with physically active jobs had about a 13% lower risk than sedentary workers.
Body Weight and Lifestyle
The relationship between obesity and prostate cancer is more nuanced than for many other cancers. Being overweight does not clearly raise the overall odds of getting prostate cancer. Some studies even suggest it slightly lowers the risk of slow-growing, low-grade tumors. But obesity has been consistently linked to more aggressive, high-grade prostate cancer and to higher mortality from the disease. Carrying excess weight may not make prostate cancer more likely, but it appears to make it more dangerous when it does occur.
Where You Live Matters
Prostate cancer incidence varies more than 25-fold between the highest and lowest incidence countries in the world. Rates are highest in Australia, the United States, and Western Europe. They are lowest in parts of Asia and Africa, though mortality rates are actually highest in less developed countries, particularly in the Caribbean and sub-Saharan Africa, where access to early detection and treatment is limited.
Migration studies offer a clue about why. When men move from low-incidence countries (like Japan) to high-incidence countries (like the U.S.), their prostate cancer risk rises within a generation or two, suggesting that diet, lifestyle, and environmental exposures play a meaningful role alongside genetics. A Western diet high in processed foods, a sedentary lifestyle, and obesity are all thought to contribute to the geographic pattern.
Survival Depends Heavily on Stage
For men diagnosed with prostate cancer that hasn’t spread beyond the prostate or nearby tissues, outcomes are excellent. The five-year survival rate for localized prostate cancer is essentially 100% across all age groups. Even regional disease, where the cancer has spread to nearby lymph nodes, carries five-year survival rates of 96% to 100% depending on age.
The picture changes dramatically for metastatic disease. When prostate cancer has spread to distant organs or bones, five-year survival drops to 36% to 47%, with younger men (under 50) surprisingly faring slightly worse than those diagnosed between 50 and 64. This gap underscores why early detection matters, particularly for men in high-risk groups. The cancer is highly treatable when caught before it spreads, and nearly all of the deaths from prostate cancer come from the relatively small fraction of cases found at an advanced stage.